"BACKGROUND AND OBJECTIVE:
Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of s...
Heterocyclic Compounds,
Receptors, CXCR4,
Hematopoietic Stem Cell Mobilization,
Lymphoma,
Multiple Myeloma,
Peripheral Blood Stem Cell Transplantation,
Receptors, CXCR4/antagonists & inhibitors,
Transplantation, Autologous,
Multiple Myeloma/therapy,
Lymphoma/therapy
La guía está dirigida al equipo de la salud que atiende directamente a los pacientes, pero también indirectamente a quienes toman decisiones administrativas, tanto en el medio hospitalario como en las aseguradoras, pagadores del gasto y en las políticas de salud. Pretende lograr un diagnóstico oport...
Zinzani, Pier Luigi;
Marchetti, Monia;
Billio, Atto;
Barosi, Giovanni;
Carella, Angelo Michele;
Lazzarino, Mario;
Martelli, Maurizio;
Rambaldi, Alessandro;
Rigacci, Luigi;
Tarella, Corrado;
Vitolo, Umberto;
Tura, Sante.
By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
Antibodies, Monoclonal,
Antibodies,
Antibodies, Monoclonal, Murine-Derived/therapeutic use,
Antineoplastic Agents,
Drug Administration Schedule,
Hematopoietic Stem Cell Transplantation,
Lymphoma, Follicular/pathology,
Lymphoma/therapy,
Neoplasm Staging,
Rituximab,
Time Factors
